HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CP 465,022

structure in first source

Also Known As:

CP-465,022; CP-465022

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - CP 465,022: 1

Experts

1.	Buchan, Alistair M: 1 article (01/2003)
2.	Chenard, Bertrand L: 1 article (01/2003)
3.	Critchett, Donald J: 1 article (01/2003)
4.	Ganong, Alan H: 1 article (01/2003)
5.	Guanowsky, Victor: 1 article (01/2003)
6.	Menniti, Frank S: 1 article (01/2003)
7.	Seymour, Patricia A: 1 article (01/2003)
8.	Welch, Willard M: 1 article (01/2003)

Related Diseases

1.	Ischemia 01/01/2003 - "However, at comparable doses, CP-465,022 failed to prevent CA1 neuron loss after brief global ischemia or to reduce infarct volume after temporary middle cerebral artery occlusion. " 01/01/2003 - "Given the high selectivity of CP-465,022 for AMPA over kainate and N-methyl-D-aspartate subtypes of glutamate receptors, the lack of neuroprotective efficacy of the compound calls into question the neuroprotective efficacy of AMPA receptor inhibition after ischemia."
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2003 - "However, at comparable doses, CP-465,022 failed to prevent CA1 neuron loss after brief global ischemia or to reduce infarct volume after temporary middle cerebral artery occlusion. "
3.	Seizures (Absence Seizure) 01/01/2003 - "CP-465,022 potently and efficaciously inhibited AMPA receptor-mediated hippocampal synaptic transmission and the induction of seizures. " 01/01/2003 - "To demonstrate that CP-465,022 gains access to the brain, the effects of systemic administration of CP-465,022 were investigated on AMPA receptor-mediated electrophysiological responses in hippocampus and on chemically induced seizures in rats. "
4.	Infarction (Infarctions) 01/01/2003 - "However, at comparable doses, CP-465,022 failed to prevent CA1 neuron loss after brief global ischemia or to reduce infarct volume after temporary middle cerebral artery occlusion. "

Related Drugs and Biologics

1.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
2.	AMPA Receptors (AMPA Receptor)
3.	Glutamate Receptors (Glutamate Receptor)
4.	N-Methylaspartate (NMDA)
5.	Kainic Acid (Kainate)